0001628280-26-023991
SEC filingTriSalus Life Sciences, Inc. appointed Dr. Richard Marshall as Chief Medical Officer effective June 29, 2026, following his prior role as Medical Director since January 2025; he will receive an annual base salary of $525,000, a $250,000 sign-on bonus, and initial equity awards of 120,000 stock options and 60,000 RSUs.
Dr. Marshall’s appointment as Chief Medical Officer marks a strategic internal promotion, reinforcing continuity in TriSalus’ clinical leadership after his tenure as Medical Director since January 2025. His deep interventional oncology background—including leadership in developing Louisiana’s first Interventional Radiology Residency and extensive experience with hepatobiliary interventions, pancreatic tumor care, and trauma—directly aligns with the Company’s focus on advancing its Pressure-Enabled Drug Delivery (PEDD) platform for liver and pancreatic cancers. The compensation package, including a $250,000 sign-on bonus and substantial initial equity (120,000 options and 60,000 RSUs), signals both the criticality of the CMO role in executing TriSalus’ dual-track strategy—integrating proprietary devices (TriNav® Infusion Systems, Pancreatic Retrograde Venous Infusion System) with its investigational immunotherapeutic nelitolimod—and management’s intent to retain clinical leadership during pivotal clinical data completion and partnership exploration phases. As noted in Exhibit 99.1, his leadership is expected to accelerate clinical and economic evidence generation for PEDD, supporting broader physician adoption and commercialization readiness.